A detailed history of Abbrea Capital, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Abbrea Capital, LLC holds 31,251 shares of ABBV stock, worth $5.36 Million. This represents 0.71% of its overall portfolio holdings.

Number of Shares
31,251
Previous 32,462 3.73%
Holding current value
$5.36 Million
Previous $5.91 Million 9.32%
% of portfolio
0.71%
Previous 0.78%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

SELL
$154.79 - $180.76 $187,450 - $218,900
-1,211 Reduced 3.73%
31,251 $5.36 Million
Q1 2024

May 07, 2024

BUY
$159.82 - $182.1 $37,557 - $42,793
235 Added 0.73%
32,462 $5.91 Million
Q4 2023

Feb 02, 2024

SELL
$137.6 - $154.97 $41,968 - $47,265
-305 Reduced 0.94%
32,227 $4.99 Million
Q2 2023

Aug 01, 2023

BUY
$132.51 - $164.9 $795 - $989
6 Added 0.02%
32,532 $4.38 Million
Q1 2023

May 11, 2023

BUY
$144.61 - $166.54 $578 - $666
4 Added 0.01%
32,526 $5.18 Million
Q4 2022

Feb 08, 2023

BUY
$138.31 - $165.87 $22,129 - $26,539
160 Added 0.49%
32,522 $5.26 Million
Q3 2022

Nov 03, 2022

SELL
$134.21 - $153.93 $56,770 - $65,112
-423 Reduced 1.29%
32,362 $4.34 Million
Q2 2022

Aug 02, 2022

SELL
$137.62 - $174.96 $62,617 - $79,606
-455 Reduced 1.37%
32,785 $5.02 Million
Q1 2022

May 11, 2022

BUY
$131.98 - $163.75 $34,974 - $43,393
265 Added 0.8%
33,240 $5.39 Million
Q4 2021

Feb 04, 2022

BUY
$107.43 - $135.93 $31,154 - $39,419
290 Added 0.89%
32,975 $4.47 Million
Q3 2021

Nov 04, 2021

BUY
$106.4 - $120.78 $38,304 - $43,480
360 Added 1.11%
32,685 $3.53 Million
Q2 2021

Aug 04, 2021

BUY
$105.21 - $117.21 $142,769 - $159,053
1,357 Added 4.38%
32,325 $3.64 Million
Q1 2021

May 13, 2021

BUY
$102.3 - $112.62 $52,786 - $58,111
516 Added 1.69%
30,968 $3.35 Million
Q4 2020

Jan 21, 2021

BUY
$80.49 - $108.67 $95,300 - $128,665
1,184 Added 4.05%
30,452 $3.26 Million
Q3 2020

Oct 20, 2020

SELL
$85.91 - $100.83 $42,955 - $50,415
-500 Reduced 1.68%
29,268 $2.56 Million
Q2 2020

Aug 11, 2020

BUY
$73.37 - $98.18 $44,315 - $59,300
604 Added 2.07%
29,768 $2.92 Million
Q1 2020

Apr 29, 2020

SELL
$64.5 - $97.79 $18,060 - $27,381
-280 Reduced 0.95%
29,164 $2.22 Million
Q4 2019

Feb 11, 2020

SELL
$72.13 - $90.25 $61,310 - $76,712
-850 Reduced 2.81%
29,444 $2.61 Million
Q3 2019

Nov 07, 2019

BUY
$62.98 - $75.72 $173,824 - $208,987
2,760 Added 10.02%
30,294 $2.29 Million
Q2 2019

Jul 31, 2019

SELL
$65.7 - $83.98 $101,506 - $129,749
-1,545 Reduced 5.31%
27,534 $2 Million
Q1 2019

May 08, 2019

BUY
$77.14 - $90.79 $30,084 - $35,408
390 Added 1.36%
29,079 $2.34 Million
Q4 2018

Feb 05, 2019

SELL
$77.85 - $96.01 $13,935 - $17,185
-179 Reduced 0.62%
28,689 $2.65 Million
Q3 2018

Nov 09, 2018

SELL
$88.91 - $98.84 $12,447 - $13,837
-140 Reduced 0.48%
28,868 $2.73 Million
Q2 2018

Aug 08, 2018

BUY
$89.78 - $106.23 $2,244 - $2,655
25 Added 0.09%
29,008 $2.69 Million
Q1 2018

May 10, 2018

BUY
$92.01 - $123.21 $59,622 - $79,840
648 Added 2.29%
28,983 $2.74 Million
Q4 2017

Feb 01, 2018

SELL
$89.56 - $98.21 $49,258 - $54,015
-550 Reduced 1.9%
28,335 $2.74 Million
Q3 2017

Nov 07, 2017

BUY
$69.85 - $89.22 $2.02 Million - $2.58 Million
28,885
28,885 $2.57 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $303B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Abbrea Capital, LLC Portfolio

Follow Abbrea Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Abbrea Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Abbrea Capital, LLC with notifications on news.